CA3151626A1 - Benzoxazinone compounds as klk5/7 dual inhibitors - Google Patents
Benzoxazinone compounds as klk5/7 dual inhibitors Download PDFInfo
- Publication number
- CA3151626A1 CA3151626A1 CA3151626A CA3151626A CA3151626A1 CA 3151626 A1 CA3151626 A1 CA 3151626A1 CA 3151626 A CA3151626 A CA 3151626A CA 3151626 A CA3151626 A CA 3151626A CA 3151626 A1 CA3151626 A1 CA 3151626A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- ppm
- acceptable complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962909006P | 2019-10-01 | 2019-10-01 | |
| US62/909,006 | 2019-10-01 | ||
| PCT/US2020/053369 WO2021067335A1 (en) | 2019-10-01 | 2020-09-30 | Benzoxazinone compounds as klk5/7 dual inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3151626A1 true CA3151626A1 (en) | 2021-04-08 |
Family
ID=75274622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3151626A Pending CA3151626A1 (en) | 2019-10-01 | 2020-09-30 | Benzoxazinone compounds as klk5/7 dual inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11643420B2 (https=) |
| EP (1) | EP4037687B1 (https=) |
| JP (1) | JP7854389B2 (https=) |
| KR (1) | KR20220091488A (https=) |
| CN (1) | CN114615984B (https=) |
| AU (1) | AU2020359526A1 (https=) |
| BR (1) | BR112022005881A2 (https=) |
| CA (1) | CA3151626A1 (https=) |
| ES (1) | ES3053975T3 (https=) |
| IL (1) | IL291398B2 (https=) |
| MX (1) | MX2022003929A (https=) |
| WO (1) | WO2021067335A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| PH12022550646A1 (en) | 2019-09-18 | 2023-04-03 | Genentech Inc | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use |
| ES3053975T3 (en) | 2019-10-01 | 2026-01-28 | Molecular Skin Therapeutics Inc | Benzoxazinone compounds as klk5/7 dual inhibitors |
| TW202304890A (zh) * | 2021-04-14 | 2023-02-01 | 美商百歐克斯製藥公司 | Klk5雙環雜芳香族抑制劑 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| CA1309556C (en) * | 1987-06-09 | 1992-10-27 | Masayuki Kokubo | 4h-3,1-benzoxazin-4-one compounds and pharmaceutical composition thereoffor the inhibition of serine proteases |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| DE4134770A1 (de) | 1991-10-22 | 1993-04-29 | Basf Ag | Koernige bleichaktivatorzusammensetzung |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| AU6242096A (en) | 1995-06-27 | 1997-01-30 | Takeda Chemical Industries Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2184851A1 (en) | 1996-09-05 | 1998-03-06 | Cheng Chung Wu | Method of manufacturing a microweavable flatware article made of synthetic material, the article produced thereby and an ink-imprinted film component for use in making the flatware article |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| PT839525E (pt) | 1996-10-31 | 2004-10-29 | Takeda Chemical Industries Ltd | Preparacao de libertacao prolongada |
| WO1998027980A2 (en) | 1996-12-20 | 1998-07-02 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| PL343317A1 (en) * | 1998-03-31 | 2001-08-13 | Warner Lambert Co | Benzoxazinones/benzothiazinones as serine protease inhibitors |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| SI1631295T1 (sl) | 2003-06-06 | 2010-06-30 | Arexis Ab | Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni |
| SI3097085T1 (sl) | 2014-01-23 | 2020-11-30 | Sixera Pharma Ab | Derivati benzoksazinona za zdravljenje kožnih bolezni |
| ES3053975T3 (en) | 2019-10-01 | 2026-01-28 | Molecular Skin Therapeutics Inc | Benzoxazinone compounds as klk5/7 dual inhibitors |
-
2020
- 2020-09-30 ES ES20872712T patent/ES3053975T3/es active Active
- 2020-09-30 JP JP2022520290A patent/JP7854389B2/ja active Active
- 2020-09-30 WO PCT/US2020/053369 patent/WO2021067335A1/en not_active Ceased
- 2020-09-30 CN CN202080069819.7A patent/CN114615984B/zh active Active
- 2020-09-30 US US17/037,910 patent/US11643420B2/en active Active
- 2020-09-30 KR KR1020227014268A patent/KR20220091488A/ko active Pending
- 2020-09-30 EP EP20872712.3A patent/EP4037687B1/en active Active
- 2020-09-30 CA CA3151626A patent/CA3151626A1/en active Pending
- 2020-09-30 AU AU2020359526A patent/AU2020359526A1/en active Pending
- 2020-09-30 BR BR112022005881A patent/BR112022005881A2/pt unknown
- 2020-09-30 IL IL291398A patent/IL291398B2/en unknown
- 2020-09-30 MX MX2022003929A patent/MX2022003929A/es unknown
-
2023
- 2023-04-03 US US18/295,009 patent/US12281123B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022005881A2 (pt) | 2022-06-21 |
| CN114615984A (zh) | 2022-06-10 |
| TW202126631A (zh) | 2021-07-16 |
| JP7854389B2 (ja) | 2026-05-01 |
| US12281123B2 (en) | 2025-04-22 |
| IL291398B1 (en) | 2025-01-01 |
| ES3053975T3 (en) | 2026-01-28 |
| JP2022551583A (ja) | 2022-12-12 |
| AU2020359526A1 (en) | 2022-04-21 |
| IL291398A (en) | 2022-05-01 |
| US20210101911A1 (en) | 2021-04-08 |
| IL291398B2 (en) | 2025-05-01 |
| EP4037687B1 (en) | 2025-10-29 |
| MX2022003929A (es) | 2022-06-14 |
| WO2021067335A1 (en) | 2021-04-08 |
| CN114615984B (zh) | 2025-02-07 |
| EP4037687A4 (en) | 2023-09-27 |
| EP4037687A1 (en) | 2022-08-10 |
| US20240067658A1 (en) | 2024-02-29 |
| US11643420B2 (en) | 2023-05-09 |
| KR20220091488A (ko) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12281123B2 (en) | Benzoxazinone compounds as KLK5/7 dual inhibitors | |
| EP3019166B1 (en) | A pharmaceutical combination for the treatment of melanoma | |
| CN111065393B (zh) | 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物 | |
| JP2022513919A (ja) | 血栓性または血小板塞栓性疾患および／または血栓性または血小板塞栓性合併症の治療および／または予防のための置換オキソピリジン誘導体 | |
| CN104039774A (zh) | Hcv ns3蛋白酶抑制剂 | |
| US20080171691A1 (en) | Inhibition of invasive remodelling | |
| CN103328466B (zh) | Hcv ns3蛋白酶抑制剂 | |
| CN114555090A (zh) | 墨蝶呤及其代谢物治疗辐射暴露的用途 | |
| WO2022200339A1 (en) | Treatment of hidradenitis suppurativa with orismilast | |
| EP4151216B1 (en) | Compound for treating and/or preventing diseases caused by coronavirus and use thereof | |
| RU2831430C1 (ru) | Соединения бензоксазинона в качестве двойных ингибиторов klk5/7 | |
| MD4802C1 (ro) | Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor | |
| EP4511031A1 (en) | Treatment of neutrophilic dermatoses | |
| US20250100963A1 (en) | Sulfonated and phosphorylated aromatic molecules | |
| EP0942746B1 (en) | Inhibition of invasive remodelling | |
| JP2022544834A (ja) | 肺疾患における好中球エラスターゼ阻害剤の使用 | |
| US20210317113A1 (en) | 1,2,3-triazole derivatives and uses thereof | |
| CN117479936A (zh) | 用奥瑞司特治疗化脓性汗腺炎 | |
| JP2025533120A (ja) | イミダゾリジニルバニリン酸エーテル誘導体の線維化を伴う疾患の治療における使用 | |
| JPWO2004093858A1 (ja) | Ｍｍｐ発現抑制剤 | |
| JPS61130268A (ja) | リジン誘導体及び抗プラスミン剤 | |
| HK1224936A1 (en) | A pharmaceutical combination for the treatment of melanoma | |
| HK1224936B (en) | A pharmaceutical combination for the treatment of melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240923 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240923 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250422 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20250923 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251218 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260420 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260420 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260420 |